Text and Data Mining valid from 2019-05-30
First Online: 30 May 2019
: A.A.-R. declares that she is named as an inventor on and receives royalties in relation to patents owned by her employer, Leiden University Medical Centre (LUMC), on exon-skipping technology, some of which have been licensed to BioMarin Pharmaceuticals and sublicensed to Sarepta. A.A.-R. also declares that she has acted as a consultant for BioClinica, BioMarin Pharmaceuticals, Eisai, Gerson Lehrman Group Consultancy, Global Guidepoint, Grunenthal, PTC Therapeutics, Sarepta and Wave and that she has been a member of the Duchenne Network Steering Committee for BioMarin and a member of the scientific advisory boards of Philae Pharmaceuticals and ProQR. Remuneration for these activities of A.A.-R., as well speaker’s honoraria from PTC Therapeutics and BioMarin Pharmaceuticals, is paid to LUMC. I.E.C.V. declares no competing interests.